BLLN
BillionToOne, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$99.39
−0.11%Year over year
Reported trailing growth
- Revenue
- +90.1%
- EBITDA
- +320.5%
- EBIT
- +253.2%
- EPS
- +200.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +28.0%
- EBITDA
- +33.7%
- EPS
- +9.8%
Three-year CAGR
- Revenue
- +106.2%
- EBITDA
- +171.9%
- EBIT
- +134.0%
- Net income
- +117.9%
- EPS
- +106.8%
- Free cash flow
- +133.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026